Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

NASDAQ | AVEO (Common Stock)
$0.92 + 0.03
Stock chart for: AVEO.O.  Currently trading at $0.92 with a 52 week high of $3.50 and a 52 week low of $0.82.
05/05/16 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAHRead More
AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North AmericaRead More
AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business UpdateRead More

Latest Event